Simon Crabb, ASCO GU22: Final Analysis of the ATLANTIS Rucaparib Arm Assessing PARP Inhibitors for Metastatic Urothelial Carcinoma

touchONCOLOGY were joined by Dr Simon Crabb (Southampton University, UK) to discuss his presentation on the rucaparib arm of the ATLANTIS study, a randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma.

Questions

1.  What is the rationale for the use of PARP inhibitors in the treatment of metastatic urothelial cancer? 00:15-01:44
2. What makes the ATLANTIS clinical trial design unique? 01:44-03:07
3. What were the efficacy and safety findings of the ATLANTIS rucaparib arm? 03:07-04:25
4. When will further results become available from the ATLANTIS clinical trial? 04:25-05:16

Speaker Disclosure: Simon Crabb discloses grant/research support from: Clovis Oncology, AstraZeneca and Roche, and is a member of the advisory board for: Bayer, Roche and AstraZeneca.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the Filmed in coverage of the ASCO Genitourinary Cancers Symposium 2022